302 related articles for article (PubMed ID: 25364229)
1. Decision-making in product portfolios of pharmaceutical research and development--managing streams of innovation in highly regulated markets.
Jekunen A
Drug Des Devel Ther; 2014; 8():2009-16. PubMed ID: 25364229
[TBL] [Abstract][Full Text] [Related]
2. Portfolio management in early stage drug discovery - a traveler's guide through uncharted territory.
Betz UA
Drug Discov Today; 2011 Jul; 16(13-14):609-18. PubMed ID: 21600301
[TBL] [Abstract][Full Text] [Related]
3. Future pharmaceutical research: the need to look beyond science.
Seeger S
Future Med Chem; 2014 May; 6(7):721-3. PubMed ID: 24941866
[No Abstract] [Full Text] [Related]
4. An unbalanced portfolio.
Federsel HJ
Drug News Perspect; 2009 Jun; 22(5):287-92. PubMed ID: 19609466
[TBL] [Abstract][Full Text] [Related]
5. Portfolio analysis and R&D decision making.
Evans R; Hinds S; Hammock D
Nat Rev Drug Discov; 2009 Mar; 8(3):189-90. PubMed ID: 19182818
[No Abstract] [Full Text] [Related]
6. Trends, challenges, and success factors in pharmaceutical portfolio management: Cognitive biases in decision-making and their mitigating measures.
Bieske L; Zinner M; Dahlhausen F; Trübel H
Drug Discov Today; 2023 Oct; 28(10):103734. PubMed ID: 37572999
[TBL] [Abstract][Full Text] [Related]
7. Effective executive management in the pharmaceutical industry.
Tran H; Kleiner BH
J Health Care Finance; 2005; 32(1):8-15. PubMed ID: 18972973
[TBL] [Abstract][Full Text] [Related]
8. Going beyond probability of success: Opportunities for statisticians to influence quantitative decision-making at the portfolio level.
Wiklund SJ; Thorn K; Götte H; Hacquoil K; Saint-Hilary G; Carlton A;
Pharm Stat; 2024; 23(3):429-438. PubMed ID: 38212898
[TBL] [Abstract][Full Text] [Related]
9. Model-based drug development survey finds pharmacometrics impacting decision making in the pharmaceutical industry.
Stone JA; Banfield C; Pfister M; Tannenbaum S; Allerheiligen S; Wetherington JD; Krishna R; Grasela DM
J Clin Pharmacol; 2010 Sep; 50(9 Suppl):20S-30S. PubMed ID: 20881214
[TBL] [Abstract][Full Text] [Related]
10. [Early achievements of the Danish pharmaceutical industry-7].
Grevsen JV; Kirkegaard H; Kruse E; Kruse PR
Theriaca; 2014; (42):31-62. PubMed ID: 25816561
[TBL] [Abstract][Full Text] [Related]
11. Factors influencing quality decision-making: regulatory and pharmaceutical industry perspectives.
Donelan R; Walker S; Salek S
Pharmacoepidemiol Drug Saf; 2015 Mar; 24(3):319-28. PubMed ID: 25628072
[TBL] [Abstract][Full Text] [Related]
12. Organizing for innovation: towards successful translational research.
West W; Nightingale P
Trends Biotechnol; 2009 Oct; 27(10):558-61. PubMed ID: 19683820
[TBL] [Abstract][Full Text] [Related]
13. Strategic biopharmaceutical portfolio development: an analysis of constraint-induced implications.
George ED; Farid SS
Biotechnol Prog; 2008; 24(3):698-713. PubMed ID: 18426243
[TBL] [Abstract][Full Text] [Related]
14. Model-based drug development: strengths, weaknesses, opportunities, and threats for broad application of pharmacometrics in drug development.
Wetherington JD; Pfister M; Banfield C; Stone JA; Krishna R; Allerheiligen S; Grasela DM
J Clin Pharmacol; 2010 Sep; 50(9 Suppl):31S-46S. PubMed ID: 20881215
[TBL] [Abstract][Full Text] [Related]
15. Patent portfolio management: literature review and a proposed model.
Conegundes De Jesus CK; Salerno MS
Expert Opin Ther Pat; 2018 Jun; 28(6):505-516. PubMed ID: 29718747
[TBL] [Abstract][Full Text] [Related]
16. Pharmaceutical research and development and the patent system.
Love J
Int J Health Serv; 2005; 35(2):257-63. PubMed ID: 15932006
[TBL] [Abstract][Full Text] [Related]
17. The clinical utility index as a practical multiattribute approach to drug development decisions.
Poland B; Hodge FL; Khan A; Clemen RT; Wagner JA; Dykstra K; Krishna R
Clin Pharmacol Ther; 2009 Jul; 86(1):105-8. PubMed ID: 19458614
[TBL] [Abstract][Full Text] [Related]
18. Towards a European strategy for medicines research (2014-2020): The EUFEPS position paper on Horizon 2020.
Gaspar R; Aksu B; Cuine A; Danhof M; Takac MJ; Linden HH; Link A; Muchitsch EM; Wilson CG; Ohrngren P; Dencker L
Eur J Pharm Sci; 2012 Dec; 47(5):979-87. PubMed ID: 23046836
[TBL] [Abstract][Full Text] [Related]
19. Risk management frameworks for human health and environmental risks.
Jardine C; Hrudey S; Shortreed J; Craig L; Krewski D; Furgal C; McColl S
J Toxicol Environ Health B Crit Rev; 2003; 6(6):569-720. PubMed ID: 14698953
[TBL] [Abstract][Full Text] [Related]
20. How to revive breakthrough innovation in the pharmaceutical industry.
Munos BH; Chin WW
Sci Transl Med; 2011 Jun; 3(89):89cm16. PubMed ID: 21715677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
